GlassScriptPhysician profile
David Lee Werwath
NPI 1164495792
$4,985.76
in general payments reported to CMS, 2019-2025
37 companies · $608 in 2025
The $608 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $608 · 2021: $990 · 2022: $941 · 2023: $686 · 2024: $672 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,068.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $338.99 | 2019-2025 | Trintellix |
| Amgen INC. | $334.89 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $332.46 | 2019-2025 | Vraylar, Botox, Qulipta |
| Glaxosmithkline, LLC. | $252.30 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $249.80 | 2019-2025 | |
| Lilly USA, LLC | $241.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $231.75 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.55 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $165.49 | 2021-2023 | Seglentis, Livalo |
| Teva Pharmaceuticals USA, INC. | $159.06 | 2019-2020 | |
| Exact Sciences Corporation | $153.12 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $125.98 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $102.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.65 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $92.04 | 2021 | |
| Irhythm Technologies, INC. | $91.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $86.18 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $78.74 | 2023-2024 | Gemtesa |
| Antares Pharma, INC. | $61.50 | 2020-2025 | Xyosted |
| Bioventus LLC | $52.21 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.67 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $48.12 | 2022 | |
| Lundbeck LLC | $42.61 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $35.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.16 | 2020 | |
| Bausch Health US, LLC | $32.00 | 2020 | |
| Genentech USA, INC. | $31.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $31.73 | 2022-2024 | Xarelto |
| Eisai INC. | $30.27 | 2020 | |
| Astellas Pharma US INC | $26.07 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.23 | 2025 | Azmiro |
| Neurelis, INC. | $22.21 | 2024 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $20.94 | 2025 | |
| Almatica Pharma LLC | $20.77 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.48 | 2021 | |
| Neos Therapeutics, LP | $16.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Werwath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.